Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tazemetostat - Epizyme

X
Drug Profile

Tazemetostat - Epizyme

Alternative Names: Davico; E-7438; EPZ-6438; EZ-438; IPN-60200; Tavico; Tazemetostat hydrobromide - Epizyme; Tazestat - Epizyme; Tazverik; Zestastat - Epizyme

Latest Information Update: 01 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Epizyme
  • Developer Eisai Co Ltd; Epizyme; Genentech; HUTCHMED; Ipsen; National Cancer Institute (USA); Pfizer
  • Class Amides; Amines; Antineoplastics; Biphenyl compounds; Dihydropyridines; Morpholines; Small molecules
  • Mechanism of Action Enhancer of zeste homolog 2 protein inhibitors; SMARCA2 protein inhibitors; SMARCA4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chordoma; Follicular lymphoma; Soft tissue sarcoma; Diffuse large B cell lymphoma; Rhabdoid tumour; Mesothelioma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Follicular lymphoma; Sarcoma
  • Registered Non-Hodgkin's lymphoma
  • Phase II CNS cancer; Diffuse large B cell lymphoma; Histiocytosis; Lymphoma; Mesothelioma; Neurofibrosarcoma; Ovarian cancer; Peritoneal cancer; Prostate cancer; Rhabdoid tumour; Solid tumours; Synovial sarcoma; Uterine cancer
  • Phase I/II Bladder cancer; Non-small cell lung cancer
  • No development reported B-cell lymphoma; Mantle-cell lymphoma

Most Recent Events

  • 28 Feb 2024 HUTCHMED plans to file NDA for relapsed/refractory Follicular lymphoma expected (second line therapy or greater) in mid-2024 in China
  • 26 Feb 2024 Epizyme completes phase-II clinical trials in Solid tumours (Second-line therapy or greater) in USA, Australia, Belgium, Canada, France, Germany, Italy, Italy, Taiwan, United Kingdom (PO) (NCT02601950)
  • 11 Dec 2023 Interim efficacy data from the phase-Ib/III SYMPHONY-1 trial in Follicular lymphoma presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top